SALEM, Mass. — Commonwealth Diagnostics International (CDI) proudly announces a new in-network agreement with Premera Blue Cross, expanding access to our hydrogen and methane breath testing for over 2.8 million lives in Washington State and Alaska. This latest agreement underscores CDI’s commitment to enhancing the accessibility and affordability of breath testing for SIBO, IMO, and fructose, sucrose, and lactose carbohydrate malabsorption.
Craig Strasnick, President & CEO of CDI, emphasized the significance of this network expansion: “Partnering with Premera Blue Cross allows us to continue our mission of providing high-quality, cost-effective diagnostics to a broader patient population. This agreement builds on our continued efforts to expand network accessibility, ensuring that more providers and their patients can access advanced, non-invasive diagnostic tools.”
This announcement follows recent in-network agreements with Blue Cross Blue Shield of Illinois and CareFirst BlueCross BlueShield, marking a period of significant growth for CDI. Additionally, CDI continues to be fully covered by Medicare and Medicare Advantage plans, with no balance billing, ensuring comprehensive access for a wide range of patients.
CDI offers innovative breath testing solutions that are FDA-registered, ISO 13485 certified, CE marked, and supported by extensive research. Our non-invasive tests provide critical diagnostic insights into functional GI conditions, ensuring personalized, effective treatments.
By partnering with Premera Blue Cross, CDI further establishes itself as the leader in hydrogen and methane breath testing, providing providers and patients with reliable, accurate diagnostics while improving access to functional GI health services across the country.
For more information, and to view our growing list of in-network providers, visit our insurance page.
About Commonwealth Diagnostics International, Inc. (CDI):
Commonwealth Diagnostics International, Inc. (CDI) is an innovative GI health company providing industry-leading diagnostic tests and tools to help physicians identify and diagnose familiar sources of digestive distress and functional GI ailments for adults and pediatric patients. Focused on their patient-centric principles, their cost-effective portfolio of diagnostic products results in expedited treatment, better patient outcomes, and robust cost savings for the healthcare delivery system. Their expansive portfolio includes non-invasive at-home breath testing kits for Small Intestinal Bacterial Overgrowth (SIBO), Intestinal Methane Overgrowth (IMO), and carbohydrate malabsorption disorders, as well as technology solutions, including MyGI Gateway, a cutting-edge provider portal for enhanced patient care, and MyGI Health, a cloud-based platform that enables patients to monitor, manage and understand their GI-related symptoms. CDI manufactures its clinically validated, FDA-registered and CE marked breath test kits according to ISO 13485 standards and perform all diagnostics in our state-of-the-art, CLIA-certified lab utilizing proprietary diagnostic technologies. For more information, visit commdx.com.
